营养状况对局部晚期食管胃腺癌围手术期FLOT治疗的病理反应和无复发生存的影响

K. Sugiyama , S. Kumar , A. Chaudry , N. Patel , P. Patel , D. Cunningham , N. Starling , S. Rao , C. Fribbens , L. Eldridge , I. Chau
{"title":"营养状况对局部晚期食管胃腺癌围手术期FLOT治疗的病理反应和无复发生存的影响","authors":"K. Sugiyama ,&nbsp;S. Kumar ,&nbsp;A. Chaudry ,&nbsp;N. Patel ,&nbsp;P. Patel ,&nbsp;D. Cunningham ,&nbsp;N. Starling ,&nbsp;S. Rao ,&nbsp;C. Fribbens ,&nbsp;L. Eldridge ,&nbsp;I. Chau","doi":"10.1016/j.esmogo.2025.100223","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment.</div></div><div><h3>Materials and methods</h3><div>We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria.</div></div><div><h3>Results</h3><div>A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, <em>P</em> &lt; 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, <em>P</em> &lt; 0.001). A decreased PNI (<em>P</em> = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, <em>P</em> = 0.75).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100223"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy\",\"authors\":\"K. Sugiyama ,&nbsp;S. Kumar ,&nbsp;A. Chaudry ,&nbsp;N. Patel ,&nbsp;P. Patel ,&nbsp;D. Cunningham ,&nbsp;N. Starling ,&nbsp;S. Rao ,&nbsp;C. Fribbens ,&nbsp;L. Eldridge ,&nbsp;I. Chau\",\"doi\":\"10.1016/j.esmogo.2025.100223\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment.</div></div><div><h3>Materials and methods</h3><div>We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria.</div></div><div><h3>Results</h3><div>A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, <em>P</em> &lt; 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, <em>P</em> &lt; 0.001). A decreased PNI (<em>P</em> = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, <em>P</em> = 0.75).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.</div></div>\",\"PeriodicalId\":100490,\"journal\":{\"name\":\"ESMO Gastrointestinal Oncology\",\"volume\":\"9 \",\"pages\":\"Article 100223\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Gastrointestinal Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949819825000925\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000925","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

营养不良在局部晚期食管胃腺癌(LA-OGA)中普遍存在,对生存的影响尚不确定。本研究旨在阐明接受5-氟尿嘧啶、亚叶酸钙、奥沙利铂和多西紫杉醇(FLOT)治疗的LA-OGA患者的生存与营养状况之间的关系。材料和方法我们从2017年至2023年在皇家马斯登医院接受根治性切除术的423例患者中筛选了接受FLOT治疗的LA-OGA (cT2-4和/或N1-3)患者。采用体重和预后营养指数(PNI)评估营养状况。主要终点为3年无复发生存率(RFS)。使用Kaplan-Meier曲线和限制平均生存时间(36个月)估计生存时间。进行多变量分析。病理反应定义为肿瘤消退等级为1-2,使用标准。结果210例患者符合纳入标准[中位随访时间26.5个月;3年RFS率为53%(95%置信区间为45% ~ 60%)。诊断时和新辅助化疗后体重减轻和PNI不是RFS的显著预测因子。新辅助化疗期间PNI的降低与维持或增加PNI的3年RFS率显著缩短相关(46%对69%,P <;0.01)。限制平均生存时间差为5.46个月(95%可信区间1.73-9.19个月,P <;0.001)。PNI下降独立预测RFS (P = 0.03)。病理反应与PNI变化无关(28.2%比30.4%,P = 0.75)。结论新辅助治疗期间PNI的变化可能与生存预后有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy

Background

Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment.

Materials and methods

We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria.

Results

A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, P < 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, P < 0.001). A decreased PNI (P = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, P = 0.75).

Conclusions

Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信